Skip to main content
Clinical Trials/NCT03668457
NCT03668457
Completed
Not Applicable

Effectiveness and Cost-effectiveness of a Multi-component Intervention to Improve Medication Adherence in People With Depressive Disorders

Servicio Canario de Salud1 site in 1 country170 target enrollmentMarch 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depressive Disorder
Sponsor
Servicio Canario de Salud
Enrollment
170
Locations
1
Primary Endpoint
Change in the Sidorkiewicz instrument score
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Objective: The study of medication adherence in depression (MAPDep study) aims to evaluate the effectiveness and cost-effectiveness of a multi-component strategy to enhance patient-centered care to improve adherence toward medications in patients with depression, formed by an educational intervention to psychiatrists and/or a collaborative care intervention group to patients and relatives plus a reminder system through the use of a mobile APP.

Methods: The objective will be assessed under an open multicenter, clinical controlled trial with random allocation by clusters to one of three interventions or to usual care (control arm). In group 1 only patients and family members receive intervention, in group 2 only psychiatrists receive intervention, and group 3 is a combined intervention for patients and psychiatrists. The main measure will be the change in medication adherence rate. Secondary endpoints are depression, emotional distress, health-related quality of life, physical functioning, patients' knowledge about their medications, provider beliefs regarding patient-centeredness, and healthcare resource utilization.

Registry
clinicaltrials.gov
Start Date
March 1, 2020
End Date
November 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Sponsor
Servicio Canario de Salud
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients:
  • Patients with diagnosis of depressive disorder (major depressive disorder MDD and/or dysthymia) under pharmacological treatment
  • Regular users of mobile phones
  • Patients who have consulted their psychiatrist about their depression at least once in the previous 6 months
  • Health professionals:
  • Psychiatrists have no intention of moving from their practice during the study period.
  • Exclusion criteria:
  • Patients with history of current bipolar disorder and/or any psychotic disorder
  • Insufficient language skills
  • Pregnancy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Change in the Sidorkiewicz instrument score

Time Frame: Baseline and 6 months

Change in adherence from baseline to 6 months. This instrument contains 5 questions to help patients recognize their different medication-taking behaviors for each drug taken. The results generate adherence levels ranging from 1 (high drug adherence) to 6 (drug discontinuation).

Secondary Outcomes

  • Change in the Sidorkiewicz instrument score(Baseline, 3 and 12 months)
  • Change in Hospital Anxiety and Depression Scale (HADS) score(Baseline, 3, 6, and 12 months)
  • Change in Physical Functioning Subscale (PF-10) of the 36-item Short Form Health Survey (SF-36)(Baseline, 6, and 12 months)
  • Change in Beck Depression Inventory - II (BDI-II) score(Baseline, 3, 6, and 12 months)
  • Change in EQ-5D-5L(Baseline, 6, and 12 months)
  • Change in Patient-Practitioner Orientation Scale (PPOS) score(Baseline and 12 months)

Study Sites (1)

Loading locations...

Similar Trials